Long-term outcome of intractable ulcerating enterocolitis of infancy

Journal of Pediatric Gastroenterology and Nutrition

Volumn 40, Issue 5, 2005, Pages 582-588

  Thapar, Nikhil ^a   Shah, Neil ^a   Ramsay, Alan D ^a   Lindley, Keith J ^a   Milla, Peter J ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Enterocolitis; Immunosuppression; Infancy; Lymphomatous proliferations

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; STEROID; TACROLIMUS; THALIDOMIDE;

B LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL FEATURE; COLON RESECTION; COLON ULCER; DISEASE COURSE; ENTEROCOLITIS; EPSTEIN BARR VIRUS; FEMALE; FOLLICULAR LYMPHOMA; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFANT DISEASE; INTRACTABLE ULCERATING ENTEROCOLITIS OF INFANCY; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; MALE; NEWBORN; NONHODGKIN LYMPHOMA; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW;

ADOLESCENT; ADULT; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; COLECTOMY; COLITIS, ULCERATIVE; CYCLOSPORINE; ENTEROCOLITIS; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFANT, NEWBORN; LYMPHOMA, NON-HODGKIN; LYMPHOPROLIFERATIVE DISORDERS; MALE; STEROIDS; THALIDOMIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 18144402820     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MPG.0000159622.88342.BC     Document Type: Review

References (29)

1. Sanderson IR, Risdon RA, Walker-Smith JA. Intractable ulcerating enterocolitis of infancy. Arch Dis Child 1991;66:295-9.
2. Sawczenko A, Sandhu BK, Logan RF, et al. Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet 2001;357:1093-4.
3. Ojuawo A, St Louis D, Lindley KJ, Milla PJ. Non-infective colitis in infancy: evidence in favour of minor immunodeficiency in its pathogenesis. Arch Dis Child 1997;76:345-8.
4. Uze, G, Kleiner DE, Kuhns DB, Holland SM. Dysfunctional LAD-1 neutrophils and colitis. Gastroenterology 2001;121:958-64.
5. D'Agata ID, Paradis K, Chad Z, Bonny Y, Seidman E. Leukocyte adhesion deficiency presenting as a chronic ileocolitis. Gut 1996;39:605-8.
6. Schappi MG, Smith VV, Goldblatt D, Lindley KJ, Milla PJ. Colitis in chronic granulomatous disease. Arch Dis Child 2001;84:147-51.
7. Schappi MG, Klein NJ, Lindley KJ, et al. The nature of colitis in chronic granulomatous disease. J Pediatr Gastroenterol Nutr 2003;36:623-31.
8. Sanderson IR, Kingston JE, Khan S, Walker-Smith JA. Hodgkin's disease complicating Crohn's disease in a child. J R Soc Med 1985;78:860-1.
9. Loftus EV Jr, Tremaine WJ, Habermann TM, et al. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 2000;95:2308-12.
10. Aithal GP, Mansfield JC. Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment. Aliment Pharmacol Ther 2001;15:1101-8.
11. Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001;121:1080-7.
12. Loftus EV Jr, Sandborn WJ. Lymphoma risk in inflammatory bowel disease: influences of referral bias and therapy. Gastroenterology 2001;121:1239-42.
13. Malatack JF, Gartner JC Jr, Urbach AH, and Zitelli BJ. Orthotopic liver transplantation, Epstein-Barr virus, cyclosporine, and lymphoproliferative disease: a growing concern. J Pediatr 1991;118:667-75.
14. Newell KA, Alonso EM, Whitington PF, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation: interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 1996;62:370-5.
15. Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343:1249-52.
16. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000;118:1018-24.
17. Bebb JR, Logan RP. Review article: does the use of immunosuppressive therapy in inflammatory bowel disease increase the risk of developing lymphoma? Aliment Pharmacol Ther 2001;15:1843-9.
18. Bebb JR, Aithal GP, Logan RP. Immunosuppression, IBD, and risk of lymphoma. Gut 2002;51:296.
19. Fraser AG, Orchard TR, Robinson EM, Jewell DP. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 2002;16:1225-32.
20. Dayharsh GA, Loftus EV Jr, Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002;122:12-7.
21. Cacciarelli TV, Reyes J, Jaffe R, et al. Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients. Pediatr Transplant 2001;5:359-64.
22. Chand DH, Southerland SM, Cunningham RJ 3rd. Tacrolimus: the good, the bad, and the ugly. Pediatr Transplant 2001;5:32-6.
23. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995;59:524-9.
24. Cox KL, Freese DK. Tacrolimus (FK506): the pros and cons of its use as an immunosuppressant in pediatric liver transplantation. Clin Invest Med 1996;19:389-92.
25. Younes BS, McDiarmid SV, Martin MG, et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation 2000;70:94-9.
26. Seto M. Molecular mechanisms of lymphomagenesis through transcriptional disregulation by chromosome translocation. Int J Hematol 2002;76(suppl 1):323-6.
27. Dirmeier U, Neuhierl B, Kilger E, et al. Latent membrane protein 1 is critical for efficient growth transformation of human B cells by Epstein Barr virus. Cancer Res 2003;63:2982-9.
28. Seite P, Million J, d'Agay, MF, et al. BCL2 gene activation and protein expression in follicular lymphoma: a report on 64 cases. Leukemia 1993;7:410-7.
29. Yano T, Jaffe ES, Longo DL, Raffeld M. MYC rearrangements in histologically progressed follicular lymphomas. Blood 1992;80:758-67.